These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23789452)

  • 21. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].
    Faber M; Jahnz-Rózyk K; Kucharczyk A; Targowski T; From S; Mamełka B
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():96-9. PubMed ID: 15524029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
    Bax R
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S118-21. PubMed ID: 17983732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.
    Schwartz RH
    Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
    Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.
    Paglia M; Peterson J; Fisher AC; Qin Z; Nicholson SC; Kahn JB
    Curr Med Res Opin; 2010 Jun; 26(6):1433-41. PubMed ID: 20394471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute otitis media.
    Biner B; Celtik C; Oner N; Küçükuğurluoğlu Y; Güzel A; Yildirim C; Adali MK
    Turk J Pediatr; 2007; 49(4):390-6. PubMed ID: 18246740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
    Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
    Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
    Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.
    Yoon HI; Lee CH; Kim DK; Park GM; Lee SM; Yim JJ; Kim JY; Lee JH; Lee CT; Chung HS; Kim YW; Han SK; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2013; 8():329-34. PubMed ID: 23874094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
    Sanches B; Coelho L; Moretzsohn L; Vieira G
    Helicobacter; 2008 Dec; 13(6):572-6. PubMed ID: 19166424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
    Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
    Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative efficacy and safety of amoxiclav (amoxicillin clavulanate) and ampicillin in the treatment of acute bacterial sinusitis].
    Kriukov AI; Sedinkin AA
    Vestn Otorinolaringol; 2004; (1):49-50. PubMed ID: 15029125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhalational antibacterial therapy for an exacerbation of chronic obstructive pulmonary disease].
    Nefedova MN; Shmelev EI
    Probl Tuberk Bolezn Legk; 2008; (8):8-11. PubMed ID: 18822473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.